Participants who took a placebo saw their A1C drop by 0.45 percent.
The findings revealed that 72 percent of participants had an A1C of 6.5 percent or lower compared with 29 percent of the placebo group. (For people living with type 2 diabetes, an A1C below 7 percent is the target.)
“The drug treats the disease that drives the diabetes and the diabetes itself,” Dr. Srivastava says.
People Are Buying Bootleg Retatrutide Online, But Experts Say ‘Don’t Do It’
The buzz around retatrutide has contributed to a thriving gray market serving people looking for serious weight loss who aren’t interested in waiting for the FDA to approve the drug. They are…
Read the full article at EVERYDAYHEALTH.COM